High prevalence of metabolic syndrome among young women with nonfatal myocardial infarction

Journal of Women's Health

Volumn 13, Issue 2, 2004, Pages 165-175

  Amowitz, Lynn L ^a   Ridker, Paul M ^a   Rifai, Nadir ^b   Loughrey, Clodagh M ^b   Komaroff, Anthony L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; CYANOCOBALAMIN; FIBRINOGEN; FOLIC ACID; GLUCOSE; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; BODY WEIGHT; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIET RESTRICTION; DISEASE SEVERITY; DYSLIPIDEMIA; ETHNOLOGY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INTERVIEW; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SMOKING; STATISTICAL SIGNIFICANCE; TEACHING HOSPITAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GLYCOPROTEINS; HOMOCYSTEINE; HUMANS; MASSACHUSETTS; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROTHROMBIN; QUESTIONNAIRES; RISK FACTORS; SERUM AMYLOID A PROTEIN; SMOKING; VITAMIN B 12;

EID: 1842504363     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/154099904322966146     Document Type: Article

References (56)

1. Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: Angiographic characterization, risk factors and prognosis. J Am Coll Cardiol 1995;26:654.
2. Vecchia CL, Franceschi S, Decarli A, Pampallona S, Tognoni G. Risk factors for myocardial infarction in young women. Am J Epidemiol 1987;125:832.
3. Arnold AZ, Moodie DS. Coronary artery disease in young women: Risk factor analysis and long-term follow-up. Clev Clin J Med 1993;60:393.
4. Wei JY, Bulkley BH. Myocardial infarction before age 36 years in women: Predominance of apparent non-atherosclerotic events. Am Heart J 1982;104:561.
5. Schwartz SM, Siscovick DS, Malinow RM, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997;96:413.
6. Zuckerman E, Toubi E, Shiram A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: A controlled prospective study. Am J Med 1996;171:381.
7. Rosenberg L, Miller,DR, Kaufman DW, et al. Myocardial infarction in women under 50 years of age. JAMA 1983;250:2801.
8. Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Stolley PD, Shapiro S. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA 1985;253:2965.
9. Johansson S, Bondjers G, Fager G, et al. Serum lipids and apolipoprotein levels in women with acute myocardial infarction. Arteriosclerosis 1988;8:742.
10. Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997;95: 329.
11. Rosenberg L, Palmer JR, Lesko SM, Shaprio S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 1990;131:1009.
12. Lewis MA, Spitzer WO, Heineman LAJ, MacRae KD, Bruppacher R, Thorogood M, on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of myocardial infarction: An international case-control study. Br Med J 1996;312:88.
13. Rosendaal FR, Siscovick DS, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2750.
14. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Voss HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747.
15. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Pressure in Adults (Adult Treatment Panel III). Bethesda, MD: National Institutes of Health. NIH Publication 01-3670.t Med. 1994;236(s736):13.
16. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356.
17. Whyte JL, L'Italien GJ, Chen RS, et al. The prevalence of the metabolic syndrome and its associated CHD risk in the United States. Diabetes 2002;51(Suppl 2):pA241.
18. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22:C10.
19. Rose GA, Blackburn H. Cardiovascular survey methods. WHO monograph series No. 58. Geneva: World Health Organization, 1982.
20. Morgan CR, Lazarow A. Immunoassay of insulin: Two-antibody system. Plasma insulin levels in normal, subdiabetic and diabetic rats. Diabetes 1963; 12:115.
21. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470.
22. Sugiuchi II, Uji Y, Okabe II, Iri T, Uekama K, Kayahara N. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated α-cyclodextrin. Clin Chem 1995;41:717.
23. 2+ method. Clin Chem 1998;44:1242.
24. Stinshoff K, Weisshaar D, Stchler F, et al. Relationship between concentration of free glycerol and triglycerides in human sera. Clin Chem 1977;23:1029.
25. Otvos JD, Jeyarajah EJ, Bennett, Kause RM. Development of a proton nuclear magnetic resonance spectroscope method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992;38:1632.
26. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue-type plasminogen activator and risk of stroke. Lancet 1994;343:940.
27. Fortin LS, Genest J Jr. Measurement of homocysteine in the prediction of arteriosclerosis. Clin Biochem 1995;28:155.
28. Ledue TB, Weiner DL, Sipe JD, Colins MF, Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A, and mannose-binding protein in human sera. Ann Clin Biochem 1998;35:745.
29. Loizou S, McCrea JD, Rudge AC, et al. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbant assay (ELISA): Standardization and quantitation of results. Clin Exp Immunol 1985;62: 738.
30. 2-glycoprotein I in the rat: Isolation from serum and demonstration in lipoprotein density fractions. J Biochem 1980;11:265.
31. Kuczmarski RJ, Flegel KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among U.S. adults: The National Health and Nutrition Examination Surveys, 1960-1991. JAMA 1994;272:205.
32. Harris MI, Hadden WC, Knowler C, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the U.S. population aged 20-74 years. Diabetes 1987;36:323.
33. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183.
34. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952.
35. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997;103:152.
36. Hafner SM, Mykkanen L, Valdez RA, et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab, 1994;79:1806.
37. Willet WC, Manson JE, Stampfer MJ, et al. Weight, weight change and coronary heart disease in women: Risk within normal range. JAMA 1995;273:461.
38. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1996;322:882.
39. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998;280:1843.
40. Knowler WC, Narayan KMV, Hanson RL, et al. Preventing non-insulin-dependent diabetes. Diabetes 1995;44:483.
41. Lillioja S, Mott D, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med 1993;329:1988.
42. Carey V, Walters E, Colditz G, et al. Body fat distribution and risk of non-insulin-dependent diabetes in women. Am J Epidemiol 1997;145:614.
43. Ashwell M, Cole TJ, Dixon AK. Obesity: New insight into anthropometric classification of fat distribution shown by computed tomography. Br Med J 1985; 290:1692.
44. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987;69:381.
45. Juhan-Vague I. Thompson SG, Jesperson J, on behalf of the ECAT Angina Pectoris Study Group. Involvement of the hemostatic system in the insulin resistance syndrome: A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993;13:1865.
46. Juhan-Vague I, Pyke SDM, Alessis MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996;94:2057.
47. Vague P, Juhan-Vague I, Aillaud MF, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986;35:250.
48. ECAT Angina Pectoris Group. ECAT Angina Pectoris Study. Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993;14:8.
49. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165.
50. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW, for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;132:635.
51. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in nondiabetic obese subjects. Thromb Haemostas 1987;57:326.
52. Sundell IB, Dahlgren S, Ranby M, Lundin E, Stenling R, Nilsson TK. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss. Fibrinolysis 1989;3:51.
53. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight U.S. white women aged 40-64. Am J Epidemiol 1995;141:1128.
54. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM, for the National Registry of Myocardial Infarction 2 Participants. Sex-based differences in early mortality after myocardial infarction. N Engl J Med 1999;341:217.
55. Sprecher DL, Pearce GL. How deadly is the "dEadly quartet"? A post-CABG evaluation. J Am Coll Cardiol 2000;36:1159.
56. Case CC, Jones PH, Nelson K, Ballantyne CM. Impact of weight loss on the metabolic syndrome. Diabetes 2002;51(Suppl 2):A608.